Right ventricular failure: a novel era of targeted therapy.
Right ventricular failure: a novel era of targeted therapy.
复制标题
DOI：
10.1007/s11897-010-0031-7
复制
发表时间：
2010-12-01
影响因子：
--
通讯作者：
Nagendran, Jayan
中科院分区：
文献类型：
--
作者：
Banerjee, Dipanjan;Haddad, Francois;Nagendran, Jayan
现在有强有力的证据认识到右心室（RV）在心脏病中的关键作用，并将其确立为一个独特的独立实体，而不是左心室（LV）。在这里，我们总结了两个心室之间的差异，右心室衰竭的诊断，急性和慢性右心室衰竭的管理。我们回顾了超声心动图用于测量RV功能的指标，以及可能在RV特异性疾病诊断和诊断中发挥作用的新型生物标志物。有一些新的治疗方法专门针对疾病中的RV。例如，5型磷酸二酯酶抑制剂改善了肺动脉高压中肥大RV的收缩性，同时保留了正常LV。肥大RV的代谢是通过代谢调节进行治疗开发的另一个领域。我们还提出了未来潜在的分子靶点，可能是独特的RV，因为他们是上调RV肥大大于LV肥大。
There now is strong evidence to recognize the pivotal role of the right ventricle (RV) in heart disease and to establish it as a unique and separate entity than the left ventricle (LV). Here, we summarize the differences between the two ventricles, the diagnosis of RV failure, and the management of acute and chronic RV failure. We review the indices derived by echocardiography used to measure RV function, and novel biomarkers that may play a role diagnosing and prognosticating in RV-specific disease. There are new novel therapies that specifically target the RV in disease. For example, phosphodiesterase type 5 inhibitors improve contractility of the hypertrophied RV while sparing the normal LV in pulmonary arterial hypertension. The metabolism of the hypertrophied RV is another area for therapeutic exploitation by metabolic modulation. We also suggest future potential molecular targets that may be unique to the RV because they are upregulated in RV hypertrophy greater than in LV hypertrophy.